LeeM.KohlerJ. (2010) Benchmarking and transparency: Incentives for the pharmaceutical industry's corporate social responsibility. Journal of Business Ethics95(4): 641–658.
2.
GolecJ.HegdeS.VernonJ. A. (2010) Pharmaceutical R & D spending and threats of price regulation. Journal of Financial & Quantitative Analysis45(1): 239–264.
3.
Puig-JunoyJ. (2010) Impact of European pharmaceutical price regulation on generic price competition. PharmacoEconomics28(8): 649–663.
4.
NexonD.UblS. J. (2010) Implications of health reform for the medical technology industry. Health Affairs29(7): 1325–1329.
5.
GrebelT.WilferT. (2010) Innovative cardiological technologies: A model of technology adoption, diffusion and competition. Economics of Innovation & New Technology19(4): 325–347.
6.
JayadevA.StiglitzJ. (2009) Two ideas to increase innovation and reduce pharmaceutical costs and prices. Health Affairs28(1): w165–w168.
7.
NairH. S.ManchandaP.BhatiaT. (2010) Asymmetric social interactions in physician prescription behavior: The role of opinion leaders. Journal of Marketing Research47(5): 883–895.
8.
DorA.EncinosaW. (2010) How does cost-sharing affect drug purchases? Insurance regimes in the private market for prescription drugs. Journal of Economics & Management Strategy19(3): 545–574.
9.
LawM. R.GrepinK. A. (2010) Is newer always better? Re-evaluating the benefits of newer pharmaceuticals. Journal of Health Economics29 (5): 743–750.
10.
DemirelP.MazzucatoM. (2010) The evolution of firm growth dynamics in the US pharmaceutical industry. Regional Studies44(8): 1053–1066.
11.
WilliamsD. R.PouderR. W. (2010) R & D spending and sources of funding of private US biopharmaceutical firms seeking to go public. Journal of Commercial Biotechnology16(4): 284–292.
12.
DenisA.MergaertL.FostierC.CleemputI.SimoensS. (2010) A comparative study of European rare disease and orphan drug markets. Health Policy97(2/3): 173–179.
13.
Jiminez-RubioD.Hernandez-QuevedoC. (2010) Explaining the demand for pharmaceuticals in Spain: Are there differences in drug consumption between foreigners and the Spanish population?Health Policy97(2/3): 217–224.
14.
SchneeE. (2010) Realizing the potential of a multinational, multicultural organization: Lessons learned at Merck Serono. Global Business & Organizational Excellence30(1): 7–16.
15.
KimC.ParkJ. H. (2010) The global research-and-development network and its effect on innovation. Journal of International Marketing18(4): 43–57.
